Effects of Chebulic Acid on Advanced Glycation Endproducts-Induced Collagen Cross-Links

被引:18
|
作者
Lee, Ji-young [1 ]
Oh, Jun-Gu [1 ]
Kim, Jin Sook [2 ]
Lee, Kwang-Won [1 ]
机构
[1] Korea Univ, Coll Life Sci & Biotechnol, Dept Food Biosci & Technol, Seoul 136713, South Korea
[2] Korea Inst Oriental Med, Diabet Complicat Res Ctr, Div Tradit Korean Med Integrated Res, Taejon 305811, South Korea
关键词
chebulic acid; Terminalia chebula; chelating activity; collagen cross-link; advanced glycation end-product; antiglycation effect; END-PRODUCTS; TERMINALIA-CHEBULA; AGE INHIBITORS; BREAKERS; ARTERIAL;
D O I
10.1248/bpb.b14-00034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Advanced glycation end-products (AGEs) have been implicated in the development of diabetic complications. We report the antiglycating activity of chebulic acid (CA), isolated from Terminalia chebula on breaking the cross-links of proteins induced by AGEs and inhibiting the formation of AGEs. Aminoguanidine (AG) reduced 50% of glycated bovine serum albumin (BSA) with glycolaldehyde (glycol-BSA)-induced cross-links of collagen at a concentration of 67.8 +/- 2.5 mM, the level of CA required for exerting a similar antiglycating activity was 38.8 +/- 0.5 mu M. Also, the breaking activity on collagen cross-links induced by glycol-BSA was potent with CA (IC50=1.46 +/- 0.05 mM), exhibiting 50-fold stronger breaking activity than with ALT-711, a well-known cross-link breaker (IC50=72.2 +/- 2.4 mM). IC50 values of DPPH. scavenging activity for CA and ascorbic acid (AA) were 39.2 +/- 4.9 and 19.0 +/- 1.29 mu g dry matter (DM) mL(-1), respectively, and ferric reducing and antioxidant power (FRAP) activities for CA and AA were 4.70 +/- 0.06 and 11.4 +/- 0.1 mmol/FeSO4 center dot 7H(2)O/g DM, respectively. The chelating activities of CA, AG and ALT711 on copper-catalyzed oxidation of AA were compared, and in increasing order, ALT-711 (IC50 of 1.92 +/- 0.20 mM)<CA (IC50 of 0.96 +/- 0.07 mM)<AG (0.47 +/- 0.05 mM). Thus, CA could be a breaker as well as an inhibitor of AGE cross-linking, the activity of which may be explained in large part by its chelating and antioxidant activities, suggesting that CA may constitute a promising antiglycating candidate in intervening AGE-mediated diabetic complications.
引用
收藏
页码:1162 / 1167
页数:6
相关论文
共 50 条
  • [41] THERMALLY LABILE CROSS-LINKS IN NATIVE COLLAGEN
    BAILEY, AJ
    LISTER, D
    NATURE, 1968, 220 (5164) : 280 - &
  • [42] PERIODATE SENSITIVITY OF CROSS-LINKS IN MATURE COLLAGEN
    HORMANN, H
    ZEITSCHRIFT FUR KLINISCHE CHEMIE UND KLINISCHE BIOCHEMIE, 1971, 9 (01): : 78 - &
  • [43] Collagen cross-links in human periodontal disease
    Jepsen, S
    Buschmann, A
    Albers, HK
    Behrens, P
    Muller, PK
    Acil, Y
    JOURNAL OF DENTAL RESEARCH, 1997, 76 (05) : 1098 - 1098
  • [44] Collagen Cross-Links Reduce Corneal Permeability
    Stewart, Jay M.
    Schultz, David S.
    Lee, On-Tat
    Trinidad, Monique L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (04) : 1606 - 1612
  • [45] Spectroscopic characterization of collagen cross-links in bone
    Paschalis, EP
    Verdelis, K
    Doty, SB
    Boskey, AL
    Mendelsohn, R
    Yamauchi, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (10) : 1821 - 1828
  • [46] SEPARATION OF THE PHENYLTHIOCARBAMYL DERIVATIVES OF COLLAGEN CROSS-LINKS
    BANES, AJ
    LINK, GW
    FEDERATION PROCEEDINGS, 1986, 45 (06) : 1683 - 1683
  • [47] NATURE AND LOCATION OF INTRAMOLECULAR CROSS-LINKS IN COLLAGEN
    BORNSTEIN, P
    KANG, AH
    PIEZ, KA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1966, 55 (02) : 417 - +
  • [48] STABLE, NONREDUCIBLE CROSS-LINKS OF MATURE COLLAGEN
    DAVIS, NR
    RISEN, OM
    PRINGLE, GA
    BIOCHEMISTRY, 1975, 14 (09) : 2031 - 2036
  • [49] PYRIDINIUM CROSS-LINKS IN HERITABLE DISORDERS OF COLLAGEN
    PASQUALI, M
    STILL, MJ
    DEMBURE, PP
    ELSAS, LJ
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (06) : 1508 - 1510
  • [50] IMMUNOASSAY OF COLLAGEN CROSS-LINKS IN ACIDIFIED URINE
    FOX, P
    STAMP, TCB
    ANNALS OF CLINICAL BIOCHEMISTRY, 1995, 32 : 326 - 328